Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Jade Biosciences, Inc.

Market Cap 911M 784M 722M 677M 1.27B 86.6B 1.28B 8.55B 3.33B 42.11B 3.42B 3.34B 145B P/E Ratio 2026 *
-5.82x
P/E Ratio 2027 * -5.87x
Enterprise Value 723M 622M 573M 537M 1.01B 68.73B 1.02B 6.79B 2.64B 33.42B 2.71B 2.65B 115B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-4.60%
1 week-9.45%
Current month-27.09%
1 month-38.81%
3 months+10.20%
6 months+2.40%
Current year-0.58%
1 week 14.28
Extreme 14.28
17.39
1 month 14.28
Extreme 14.28
24.81
Current year 12.45
Extreme 12.45
28
1 year 6.61
Extreme 6.61
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer 53 22/04/2026
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
06-09
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
06-09Free

Director

34,843 0.0706%
06-09Free

Chairman

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-4.60%-9.45%+126.92% - 911M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.25%+0.36%+65.30%+89.18% 21.34B
Weighted average by Cap. +1.03%+1.43%+57.62%+96.08%

Financials

2026 *2027 *
Net sales - -
Net income -172M -148M -137M -128M -240M -16.38B -243M -1.62B -629M -7.97B -646M -633M -27.52B -191M -165M -152M -142M -267M -18.21B -270M -1.8B -699M -8.85B -718M -703M -30.59B
Net Debt -188M -162M -149M -140M -262M -17.87B -265M -1.77B -686M -8.69B -705M -690M -30.02B -429M -370M -341M -319M -599M -40.84B -606M -4.03B -1.57B -19.86B -1.61B -1.58B -68.61B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
12/06/26 15.34 $ -4.60% 1,046,551
11/06/26 16.08 $ +5.37% 806,446
10/06/26 15.26 $ +0.26% 1,375,102
09/06/26 15.22 $ +1.60% 1,598,187
08/06/26 14.98 $ -11.57% 1,466,488
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.34USD
Average target price
49.00USD
Spread / Average Target
+219.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!